$30.06
Today
as of Sep 4, 16:48 ET
Last 30 days
Recent Press Releases & News
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Damora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis
Overview
52-week range
$2.45
$38
77% of range
Avg surprise (last 1)
-195.2%
Avg reaction (last 2)
-0.0%
50% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.39 | — | — | — | — | financials |
| Tue May 12, 2026 | Mar/2026 | $-0.62 | $-0.21 | -195.2% | +67.7% | -5.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-2.36 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-2.60 | — | — | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-1.92 | — | — | — | +5.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-3.39 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-4.92 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-5.05 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-7.50 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.41 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.51 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-35M | $-31M | — | $-3M | $-3M | $-3M | — | $-4M |
| Net income | $-31M | $-28M | — | $-3M | $-3M | $-3M | — | $-4M |
| EPS (diluted) | $-0.39 | $-0.62 | — | $-2.36 | $-2.60 | $-1.92 | — | $-3.39 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $541M | $533M | $258M | $8M | $10M | $12M | $14M | $20M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $544M | $535M | $260M | $10M | $13M | $15M | $17M | $21M |
| Total assets | $544M | $535M | $261M | $11M | $14M | $15M | $17M | $23M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $28M | $24M | $20M | $3M | $3M | $2M | $1M | $2M |
| Total equity | $516M | $512M | $240M | $8M | $11M | $14M | $16M | $21M |
Implied volatility — last 90 days
No IV snapshots yet for DMRA.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.